ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos953 M919 M959 M973 M1.12 B3.97 BInvestigación y desarrollo247 M247 M244 M256 M266 M1.01 BBeneficio operativo-29 M519 M455 M882 M301 M2.16 BTotal de ingresos no operativos-218 M-225 M-252 M-237 M-220 M-934 MGastos por intereses, netos de intereses capitalizados——————Ingresos no operativos, una vez deducidos los gastos por intereses-218 M-225 M-252 M-237 M-220 M-934 MIngresos/gastos extraordinarios——————Beneficio antes de impuestos-247 M294 M204 M648 M92 M1.24 BParticipación en los beneficios001 M2 M12 M15 MImpuestos29 M74 M-78 M214 M-390 M-180 MParticipación minoritaria-58 M6 M01 M07 MOtros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas-392 M214 M282 M433 M481 M1.41 BOperaciones suspendidas175 M00000Beneficio neto-217 M214 M282 M433 M481 M1.41 BAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-217 M214 M282 M433 M480 M1.41 BBeneficio básico por acción-0.190.190.250.380.411.23Beneficio por acción diluido-0.190.180.240.370.421.21Número medio de acciones ordinarias1.13 B1.14 B1.15 B1.15 B1.15 B4.58 BAcciones diluidas1.13 B1.16 B1.16 B1.16 B1.16 B4.65 BEBITDA-20 M1.3 B1.44 B1.77 B-1.95 B2.57 BEBIT-164 M1.16 B1.29 B1.63 B-2.09 B1.99 BCosto de los ingresos2.11 B2.01 B2.07 B2.18 B2.06 B8.32 BOtros costes de producción——————Amortización y depreciación (flujo de caja)144 M145 M148 M144 M144 M581 M
Teva Pharmaceutical Industries Limited American Depositary Shar
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States.
Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America.
Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs.